<DOC>
	<DOCNO>NCT01289730</DOCNO>
	<brief_summary>The study aim investigate efficacy safety etanercept patient active undifferentiated spondyloarthritis ( uSpA ) period 520 week .</brief_summary>
	<brief_title>Etanercept ( Enbrel ) Undifferentiated Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Patients 18 65 year age . 2 . Proven undifferentiated spondyloarthritis accord European Spondylarthropathy Study Group ( ESSG ) criteria ankylose spondylitis , reactive arthritis , psoriasis and/or inflammatory bowel disease 3 . Acute phase disease high disease activity Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score ≥ 4 pain score ≥ 4 Numeric Rating Scale ( NRS ) two occasion 2 week 4 . Understand , sign date write informed consent screen visit . 5 . Sexually active woman participate study must use medically acceptable form contraception 6 month last injection study medication . Medically acceptable form contraception include oral contraceptive , injectable implantable method , intrauterine device , properly use barrier contraception . Additionally , use condom suggest adjunct method previously address protect sexually transmit disease provide additional protection accidental pregnancy . 6 . Sexually active men must agree use medically accept form contraception study 6 month last injection study medication . 7 . Negative serum urine pregnancy test take screen woman except surgically sterile least 1 year postmenopausal . 8 . Able selfadminister injectable drug supply caregiver . 9 . Able store injectable test article 2° 8° C. 1 . Pregnancy/lactation 2 . Previously exposure murine chimeric monoclonal antibody 3 . Receipt live ( attenuate ) vaccine within 4 week screen visit 4 . History chronic recent serious infection 5 . History tuberculosis within last 3 year 6 . History malignancy 7 . Significant concurrent medical disease include uncompensated congestive heart failure , myocardial infarction within 12 month , stable unstable angina pectoris , uncontrolled hypertension , severe pulmonary disease , history human immunodeficiency virus ( HIV ) infection , central nervous system demyelinate event suggestive multiple sclerosis 8 . Presence history confirm blood dyscrasia 9 . History viral hepatitis within 1 year prior screen history druginduced liver injury time prior screen 10 . Laboratory exclusion : hemoglobin level &lt; 8,5 mg/dl white blood cell count &lt; 3.5 x 10^9/l platelet count &lt; 125 x 10^9 /l creatinine level &gt; 175 mcmol/l , liver enzymes &gt; 1.5 time upper limit normal alkaline phosphatase &gt; 2 time upper limit normal . 11 . Participation trial investigational medication within 30 day enter study 12 . Clinical examination show significant abnormality clinical relevance 13 . Concomitant medication diseasemodifying antirheumatic drug ( DMARDs ) corticosteroids 14 . History current evidence abuse `` hard '' drug ( eg. , cocaine/heroine ) alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>undifferentiated spondyloarthritis</keyword>
	<keyword>etanercept</keyword>
	<keyword>therapy</keyword>
	<keyword>magnetic resonance imaging</keyword>
</DOC>